

Diabetes mellitus and colorectal cancer – a revealed connection

Mihăiță Pătrășescu¹, Petruț Nuță¹, Raluca S. Costache^{1,2}, Săndica Bucurică^{1,2}, Bogdan Macadon¹, Andrada Popescu¹, Vasile Balaban^{1,2}, Florentina Ioniță Radu^{1,3}, Mariana Jinga^{1,2}

Abstract: *The burden of colorectal cancer (CRC) is increasing all over the world. The prevalence of diabetes mellitus is increasing. It is estimated that diabetes affects 387 million people worldwide. It is predicted that 552 million people worldwide will develop diabetes by 2030. A large pool of data indicate that DM increases by 2 fold the risk of CRC. This is the reason to firmly suggest the inclusion of DM in the criteria for CRC screening as an important measure to decrease the mortality of this ailment.*

INTRODUCTION

Type 2 diabetes mellitus and colorectal cancer are major causes of morbidity and mortality in the United States and other Western countries.

The burden of colorectal cancer (CRC) is increasing all over the world. It is recognized as the second cause of cancer death in USA and in Western Europe. Also, it is a third cause of cancer in men and a second cause of cancer in women. Every year there are 1,2 million new cases in the world. The highest incidence is encountered in Australia (75/100000), New Zealand, North America and Europe¹. In Romania the incidence has doubled from 1994 (13/100000) to 2005 (23/100000)². The lifetime risk of CRC is 5%. 90% of cases appear after the age of 50; beneath this age threshold is rare encountered but the current trend indicates an increasing prevalence in young³.

It is estimated that diabetes affects 387 million people worldwide. It is predicted that 552 million people worldwide will develop diabetes by 2030. In

the United States, about 23.6 million people or 7.8% of adults have DM and by 2050, the number of people in the United States with diagnosed DM is estimated to grow to 48.3 million⁴. The prevalence of diabetes mellitus in Romania is 11.6% as PREDATTOR Study has concluded in 2014⁵. Even those figures are very high it is appreciated that almost one-third of diabetics is undiagnosed⁶.

STUDIES THAT CONFIRM THE RELATION BETWEEN DM AND CRC

In 1910, Maynard⁷ provided the earliest reports on the association between DM and cancer of any type. In 1984, Williams et al⁸ published a retrospective study that documented a statistically significant, over 2-fold increase in the prevalence of DM in CRC

¹ Carol Davila Central Emergency Military Hospital, Bucharest


² Carol Davila University of Medicine and Pharmacy, Bucharest

² Titu Maiorescu University, Faculty of Medicine, Bucharest

patients compared with age-matched controls. The search for a pathological explanation for this connection has led to the so-called hyperinsulinemia hypothesis. Giovannucci⁹ hypothesized that insulin, an important growth factor, may at high serum concentrations increase the risk of CRC by promoting

growth of colon tumors, and acting as a cell mitogen. Other proposed explanations for the increased risk include decreased bowel transit time and elevated fecal concentrations of bile acids¹⁰. Yang et al.¹¹ showed that insulin treatment may further elevate risk for CRC among patients with type 2 DM.

Figure 1: Risk factors for DM and CRC



Overall, studies indicate that diabetes risk increases twofold for liver, pancreatic, and endometrial cancer and 1.2- to 1.5-fold for colorectal, breast, and bladder cancer, but is associated with decreased risk for prostate cancer¹². Diabetes is an independent risk factor for liver cancer. Cancer patients with diabetes relapse, and die, sooner than those without the disease.

Although proving a causal connection in observational human studies is uncertain and may take decades, preclinical research is revealing possible biochemical links between cancer and diabetes, which also share many risk factors.

The American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008 recommend that clinicians be aware of an increased risk of CRC in cigarette smokers and obese patients¹³, but do not highlight the increased risk in patients with DM. Obesity and smoking are associated with the incidence of both type 2 DM and CRC¹⁴; thus, they also could be important positive confounders of the

association between DM and CRC.

In July 2010, the American Cancer Society and the American Diabetes Association released a consensus report that reviewed the science behind the link and evidence for whether diabetes treatments influence cancer risk or prognosis. Published in the July August 2010 *CA: A Cancer Journal of Clinicians*, the report recommended regular cancer screening for diabetics. Preliminary evidence that metformin is associated with lower cancer risk, and exogenous insulin with higher risk¹².

Diabetes is characterized by high levels of both insulin and blood sugar, and both promote cancer cell proliferation in preclinical models. In a Nov. 29, 2011, *British Journal of Cancer* study, he examined levels of the two in nearly 5,000 women from the Women's Health Initiative over 12 years. Elevated glucose levels were associated with a nearly doubled risk of colorectal cancer¹².

A recent meta-analysis on 41 studies associated DM with an increased incidence of colorectal cancer

[relative risk, 1.27; 95% confidence interval (CI), 1.21–1.34]¹⁵. No associations between DM and colon cancer were evident among African Americans¹⁶. A large-scale, population-based study in Japan suggested that diabetic men carried a higher risk for colorectal cancer than diabetic women did. The incidence of colorectal cancer was significantly higher in DM patients than in control patients (HR, 2.10; 95% CI, 1.82–2.42). The incidence of colorectal cancer is higher in males than in females (adjusted HR, 1.34; 95% CI, 1.18–1.53)¹⁷.

CRC risk was higher among diabetics with longer duration of disease¹⁸.

Metanalysis¹⁹ of 15 studies (six case – control and nine cohort studies), including 2 593 935 participants, found that diabetes was associated with an increased risk of colorectal cancer, compared with no diabetes (summary RR of colorectal cancer incidence = 1.30, 95% CI = 1.20 to 1.40), without heterogeneity between studies (*P* heterogeneity = 0.21). The association between diabetes and colorectal cancer incidence did not differ statistically significantly by sex (summary RR among women = 1.33, 95% CI = 1.23 to 1.44; summary RR among men = 1.29, 95% CI = 1.15 to 1.44; *P* heterogeneity = .26) or by cancer subsite. Diabetes was positively associated with colorectal cancer mortality (summary RR = 1.26, 95% CI = 1.05 to 1.50), but there was evidence for heterogeneity between studies (*P* heterogeneity = 0.04). Findings from this meta-analysis indicate that individuals with diabetes have an approximately 30% increased relative risk of developing colorectal cancer compared with nondiabetic individuals.

Risk factors such as obesity, physical inactivity, smoking, Western diet and metabolic syndrome are common in both DM and colorectal cancer patients.

THE PROBLEM OF CONFOUNDERS AS RISK FACTORS

The first metaanalysis to quantitatively assess the effect of certain potentially important confounding variables including obesity, smoking, and physical exercise was published in 2008. It showed a statistically significant association between DM and

risks of colon cancer and rectal cancer separately after controlling for obesity, smoking, and physical exercise. The association of DM and cancer risk was stronger for colon cancer than for rectal cancer (summary RR 1.38, 95 % CI 1.26 – 1.51 vs. summary RR 1.20, 95 % CI 1.09–1.31, respectively). This difference may be because the proximal colon, distal colon, and rectum have different embryological origins²⁰.

The positive association of DM with colon cancer and rectal cancer risk did not decrease when the metaanalysis was limited to studies that controlled for smoking and BMI (summary RR for colon 1.34, 95 % CI 1.17–1.52, and summary RR for rectum 1.28, 95% CI 1.06–1.54). This suggests that the confounding effect of obesity and smoking is relatively weak, and that DM appears to be an independent risk factor for colon cancer and rectal cancer.

Furthermore, as a recent study indicated, persons with DM and CRC may be at increased risk for CRC recurrence, non-response to chemo and radiotherapy treatment, and treatment-related complications. CRC deaths may be reduced through CRC screening programs.²¹

PROPOSED MECHANISMS

Several mechanisms have been proposed to explain the potential relationship between DM and colorectal cancer. Hyperinsulinemia, insulin-like growth factor-1, glucagon-like peptide-1 and the relative binding proteins each play an important role in metabolism, cell growth, proliferation and the regulation of the apoptotic process in colon cells²².

Mechanistically, insulin stimulates cell proliferation through two pathways. One pathway involves direct binding of insulin to insulin or insulin-like growth factor-1 (IGF-1) receptors, and the other pathway is via inhibition of IGF binding proteins and the resultant increase in IGF-1 availability to the IGF receptor. The IGF system is a potent growth regulator closely linked with carcinogenesis²³. These data support the notion that IGF-1 has a role in the biological pathway of colorectal neoplasia, beginning at the adenoma stage.

CONCLUSION

The increasing prevalence of DM may, significantly, be responsible for the increasing prevalence of CRC

and its mortality. A great pool of data may suggest a need for more intensive CRC screening program in patients with type 2 DM, especially those who receive chronic insulin therapy.

References:

1. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
2. Catalina Zaharia, Aurel Mironiuc, Raluca Pais, Dan L. Dumitrascu, Is colorectal cancer associated with diabetes mellitus ? University of Medicine and Pharmacy "Iuliu Hațieganu" Cluj-Napoca, Romania Center for the Research of Chronic Diseases, 2nd Dept. of Internal Medicine and 2nd Dept. of Surgery Clujul Medical 2012 Vol. 85 - nr. 1
3. Pais R, Silaghi H, Silaghi AC, et al. Metabolic syndrome and risk of subsequent colorectal cancer. *World J Gastroenterol.* 2009; 15(41): 5141–5148.
4. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. *Phys Ther.* 2008; 88:1254–64
5. Maria Mota, Ilie-Robert Dinu. The analysis of prevalence and incidence of diabetes mellitus in Romania. *Rom J Diabetes Nutr Metab Dis.* 2013; 20(2):135-139
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2005; 28 (suppl 1):S37–42.
7. Maynard GD. A statistical study in cancer death-rates. *Biometrika.* 1910; 7:276–304.
8. Williams JC, Walsh DA, Jackson JF. Colon carcinoma and diabetes mellitus. *Cancer.* 1984; 54:3070–1.
9. Giovannucci E. Insulin and colon cancer. *Cancer Causes Control.* 1995; 6:164–79.
10. Will JC, Galuska DA, Vinicor F, et al. Colorectal cancer: another complication of diabetes mellitus? *Am J Epidemiol.* 1998; 147:816–25.
11. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. *Gastroenterology.* 2004
12. Vicki Brower. Illuminating the Diabetes–Cancer Link. *JNCI* Vol. 104, Issue 14 | July 18, 2012; 1048-50
13. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening [corrected]. *Am J Gastroenterol.* 2009; 104:739–750
14. Keller U. From obesity to diabetes. *Int J Vitam Nutr Res.* 2006; 76:172–7
15. Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. *Eur J Epidemiol* 2011
16. . Vinikoor LC, Long MD, Keku TO, Martin CF, Galanko JA, Sandler RS. The association between diabetes, insulin use, and colorectal cancer among Whites and African Americans. *Cancer Epidemiol Biomarkers Prev* 2009;18:1239–42.
17. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. *Arch Intern Med* 2006;166:1871–7
18. Wideroff L, Gridley G, Møller M, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. *J Natl Cancer Inst.* 1997; 89:1360–5
19. Susanna C. Larsson, Nicola Orsini, Alicja Wolk Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis, Sweden. *Journal of the National Cancer Institute*, Vol. 97, No. 22, November 16, 2005
20. Botteri E, Iodice S, Bagnardi V, et al. Smoking and colorectal cancer: a meta-analysis. *JAMA.* 2008; 300:2765–78
21. Stein KB, Snyder CF, Barone BB, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. *Dig Dis Sci.* 2009
22. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. *J Surg Oncol.* 2004; 88:261–6
1. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. *J Natl Cancer Inst.* 2002; 94:972–80.